JUBLPHARMA - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 2.9
| Stock Code | JUBLPHARMA | Market Cap | 13,551 Cr. | Current Price | 851 ₹ | High / Low | 1,250 ₹ |
| Book Value | 141 ₹ | Dividend Yield | 0.59 % | ROCE | 2.91 % | ROE | 1.04 % |
| Face Value | 1.00 ₹ | DMA 50 | 914 ₹ | DMA 200 | 1,008 ₹ | Chg in FII Hold | -0.60 % |
| Chg in DII Hold | 0.70 % | PAT Qtr | 6.60 Cr. | PAT Prev Qtr | -48.0 Cr. | RSI | 43.9 |
| MACD | -24.2 | Volume | 1,36,617 | Avg Vol 1Wk | 1,57,350 | Low price | 784 ₹ |
| High price | 1,250 ₹ | Debt to equity | 0.02 | 52w Index | 14.4 % | Qtr Profit Var | 154 % |
| EPS | 1.23 ₹ | Industry PE | 27.2 |
📊 Jubilant Pharmova (JUBLPHARMA) shows weak technical momentum for swing trading. The RSI at 43.9 indicates mildly oversold conditions, while the MACD (-24.2) is negative, suggesting bearish sentiment. The stock is trading below both its 50 DMA (914 ₹) and 200 DMA (1,008 ₹), reflecting weakness. The optimal entry price would be around 835–850 ₹. If already holding, consider exiting near 900–920 ₹, where resistance is expected, unless momentum strengthens.
✅ Positive
- Book value of 141 ₹ provides valuation support.
- Dividend yield of 0.59% offers modest income.
- Quarterly PAT improved from -48 Cr. to 6.6 Cr., showing recovery.
- DII holdings increased (+0.70%), signaling domestic investor confidence.
- Debt-to-equity ratio of 0.02 indicates very low leverage.
⚠️ Limitation
- Stock trading below both 50 DMA and 200 DMA.
- ROCE (2.91%) and ROE (1.04%) are weak relative to peers.
- EPS of 1.23 ₹ is modest compared to industry standards.
- Volume slightly below 1-week average, indicating weaker participation.
📉 Company Negative News
- Quarterly profit variation at 154% reflects volatility from prior losses.
- FII holdings decreased (-0.60%), showing reduced foreign investor interest.
- Stock price significantly below 52-week high of 1,250 ₹.
📈 Company Positive News
- Quarterly PAT turned positive after a loss in the previous quarter.
- Institutional inflows from domestic investors provide support.
- Stock trading well above 52-week low of 784 ₹, showing recovery potential.
🏭 Industry
- Industry PE at 27.2 vs. JUBLPHARMA’s undefined PE suggests uncertainty in valuation.
- Pharma sector benefits from long-term demand in healthcare and global supply chains.
🔎 Conclusion
Jubilant Pharmova has shown signs of recovery but weak fundamentals, low profitability, and technical weakness limit its swing trade appeal. Entry near 835–850 ₹ could be considered if reversal signs appear. Exit strategy should target 900–920 ₹ unless momentum strengthens. Long-term investors may hold for sectoral growth, but short-term traders should remain cautious due to earnings volatility and weak returns.